ONCOLYTICS BIOTECH INC

Oncolytics Biotech shares fall 1.96% amid sector‑wide pullback as investors await new clinical data on its REOLYSIN cancer therapy.

Oncolytics Biotech (ONCY) climbs 2% as investors eye its REOLYSIN reovirus therapy, hinting at a potential breakout driven by Phase III trials and new partnerships.

Oncolytics Biotech’s virus‑based immunotherapy pelareorep shows promising Phase‑2 data for metastatic colorectal cancer, with an upcoming ESMO presentation that could spark a stock rally.

Oncolytics Biotech (ONCY) stays flat at $0.50 after a volatile month, offering investors a steady benchmark while awaiting key clinical milestones for REOLYSIN.